Kezar Life Sciences(KZR)

Search documents
Kezar Life Sciences (KZR) Corporate Overview
2021-09-10 20:03
& KEZAR Selective Targets. Broad Impact. Uniquely Powerful Approaches to Tackling the Toughest Diseases Corporate Overview September 2021 www.kezarlifesciences.com Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circums ...
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
2020-09-11 21:46
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Corporate Presentation September 2020 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statem ...
Kezar Life Sciences(KZR) - 2020 Q2 - Earnings Call Transcript
2020-08-09 09:32
Financial Data and Key Metrics Changes - Cash, cash equivalents, and marketable securities totaled $157.5 million as of June 30, 2020, compared to $78.2 million as of December 31, 2019, primarily due to net proceeds from public offerings [37] - Net loss for Q2 2020 was $9.5 million or $0.22 per share, compared to a net loss of $8.7 million or $0.46 per share for Q2 2019 [39] Business Line Data and Key Metrics Changes - Research and development expenses for Q2 2020 increased by $200,000 to $7.1 million compared to $6.9 million in Q2 2019, mainly due to advancing the protein secretion pre-clinical program [38] - General and administrative expenses for Q2 2020 increased by $300,000 to $2.7 million compared to $2.4 million in Q2 2019, primarily due to increased personnel expenses [38] Market Data and Key Metrics Changes - The company is focusing on the development of KZR-616 for severe autoimmune diseases and KZR-261 for solid tumors, with ongoing clinical trials impacted by COVID-19 [11][14] Company Strategy and Development Direction - The company aims to pioneer small molecule approaches against novel targets, with a focus on KZR-616 and KZR-261, to address severe autoimmune diseases and cancers [14][41] - The strategy includes reevaluating clinical development plans in light of new data and the ongoing pandemic, with a commitment to patient safety and effective treatment [12][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of their drug candidates and the ongoing commitment to advancing clinical programs despite challenges posed by COVID-19 [9][41] - The company is well-capitalized with a strong balance sheet, providing a runway to achieve its goals [15][37] Other Important Information - The MARINA study has been withdrawn due to a lack of patient enrollment and the need for protocol amendments [30] - The company plans to submit an IND for KZR-261 in Q1 2021 and initiate a first-in-human clinical trial shortly thereafter [34][55] Q&A Session Summary Question: What factors contributed to better tolerability on Cohort 2c? - Better tolerability was due to a combination of moving to a lyophilized formulation, step-up dosing, and supportive measures for patients [43] Question: Does the new formulation make the drug more stable? - The new formulation does not change stability but simplifies the formulation by removing an excipient that could cause adverse reactions [45] Question: When can we expect another update from the Stage 1b MISSION study? - An interim update is expected by the end of the year, with initial data anticipated in the first half of 2021 [50] Question: How has the PRESIDIO timeline been impacted by COVID-19? - Enrollment has slowed, pushing the completion timeline from the end of 2021 to mid-2022, but data integrity is not expected to be affected [51] Question: What is the rationale for the 50% reduction in proteinuria as a primary endpoint? - A 50% reduction in proteinuria is a standard measure of renal response based on past clinical trials [58] Question: Why was the MARINA study withdrawn? - The study was withdrawn due to a high screening failure rate and the need for a more inclusive protocol [59][77]
Kezar Life Sciences(KZR) - 2020 Q2 - Earnings Call Presentation
2020-08-06 22:14
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Corporate Presentation August 2020 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statement ...
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
2020-03-05 15:19
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Corporate Presentation March 2020 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements ...
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
2019-10-18 18:57
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Investor Presentation October 2019 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statement ...
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
2019-09-16 16:46
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Investor Presentation September 2019 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking stateme ...
Kezar Life Sciences (KZR) Presents At EULAR 2019 - Slideshow
2019-06-14 17:17
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Phase 1b MISSION Study Data EULAR 2019 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking state ...